THERANOSTICS MARKET ANALYSIS

Theranostics Market, by Therapeutic Area (Oncology (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Others), Cardiovascular Diseases, Neurological Disorders, Immunological Disorders, and Others), by Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry, In Situ Hybridization, Sequencing, and Others), by End Users (Hospitals, Diagnostic Laboratories, and Others), by Region (North America, Europe, Latin America, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Key Developments:-

In 2018, THERADIAG, a company specialized in vitro diagnostics and theranostics entered into partnership agreement with Biogaran to supply its Lisa Tracker kits for Biogaran biosimilar monitoring.
In 2018, Novartis AG, entered into an agreement with Endocyte, a US-based Biopharmaceutical Company which develops targeted therapeutics for cancer treatment.
In 2018 RadioMedix Inc. and AREVA Med LLC, announced the Phase 1 trial for AlphaMedixTM in patients with somatostatin receptor positive neuroendocrine tumors in the U.S. AlphaMedixTM is composed of a somatostatin (SST) analogue radiolabeled with 212Pb, an isotope used for Targeted Alpha-emitter Therapy (TAT).
In 2016, avant diagnostics and Amarantus Diagnostics have signed a letter of intent to acquire theranostics health, a protein analysis service provider.